Human CTLA4

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multistep process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 28°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ 70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only (RUO). NonTherapeutic.

28°C Wet Ice

This nontherapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA4. This product is for research use only.

Cytotoxic Tlymphocyte–associated antigen 4 (CTLA4) is a protein receptor that serves as an immune checkpoint and downregulates the immune system. CTLA4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”² Emerging research suggests that combined blockade of PD1 and CTLA4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.¹ This costeffective, researchgrade AntiHuman CTLA4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.

CTLA4 is constitutively expressed in regulatory T cells.

1. Wolchok, JD. et al. (2013) N Engl J Med 369(2):12233.
2. Soo, RA. et al. (2017) Lancet Oncol. 18(12):e731e741.
3. Lipson, EJ. and Drake, CG. (2011) Clin Cancer Res 17(22):695862.